Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
4,611
Completed, industry sponsors, Oncology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting1,443
- Completed4,611
4,611 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT03386513 · 179 participants · Start Jan 2, 2018 · Primary completion Oct 2, 2024
Drug: IMGN632 · For: Blastic Plasmacytoid Dendritic Cell Neoplasm; Myeloproliferative Neoplasm
Sites: Birmingham, Alabama; Gilbert, Arizona; Duarte, California · 18 sites in all
Strand Therapeutics Inc.Industry
NCT06249048 · 39 participants · Start May 3, 2024 · Primary completion Jun 17, 2026
Drug: STX-001; Keytruda® · For: Advanced Solid Tumor
Sites: Scottsdale, Arizona; Beverly Hills, California; Cleveland, Ohio · 7 sites in all
- GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabPivotal-lookingCompleted
NETRIS PharmaIndustry
NCT04652076 · 238 participants · Start Dec 14, 2020 · Primary completion Oct 30, 2025
Drug: NP137; Pembrolizumab and 2 more · For: Endometrial Carcinoma; Cervix Carcinoma
Sites: Besançon, France; Bordeaux, France; Caen, France · 15 sites in all
GPCR Therapeutics, Inc.Industry
NCT05561751 · 28 participants · Start Feb 13, 2023 · Primary completion Sep 30, 2025
Drug: GPC-100; Propranolol and 1 more · For: Multiple Myeloma
Sites: La Jolla, California; Gainesville, Florida; Indianapolis, Indiana · 10 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02568267 · 534 participants · Start Nov 19, 2015 · Primary completion Oct 29, 2026
Drug: Entrectinib · For: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer and 13 more
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 115 sites in all
Corbus Pharmaceuticals Inc.Industry
NCT06603844 · 51 participants · Start Dec 4, 2024 · Primary completion Jan 30, 2026
Drug: CRB-601 monoclonal antibody; Anti-PD-1 monoclonal antibody · For: Solid Tumor
Sites: Birmingham, Alabama; Tucson, Arizona; La Jolla, California · 26 sites in all
Arvinas Inc.Industry
NCT07023731 · 76 participants · Start May 29, 2025 · Primary completion Oct 30, 2026
Drug: ARV-806 · For: KRAS G12D Mutation; Advanced Solid Cancer
Sites: Phoenix, Arizona; New Haven, Connecticut; Tampa, Florida · 14 sites in all
PureTechIndustry
NCT04666688 · 44 participants · Start Dec 11, 2020 · Primary completion Dec 12, 2024
Drug: LYT-200; Tislelizumab · For: Metastatic Cancer; Solid Tumor; Head and Neck Cancer
Sites: Los Angeles, California; Denver, Colorado; Sarasota, Florida · 13 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04895722 · 302 participants · Start Jun 25, 2021 · Primary completion May 21, 2025
Drug: Pembrolizumab; Pembrolizumab/Quavonlimab and 3 more · For: Colorectal Cancer
Sites: Orange City, Florida; Athens, Georgia; Chicago, Illinois · 109 sites in all
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT05794477 · 16 participants · Start Apr 28, 2023 · Primary completion Aug 20, 2024
Drug: Adebrelimab; SHR-1802 and 2 more · For: Advanced Solid Tumor
Sites: Changsha, China
BioXcel Therapeutics IncIndustry
NCT03910660 · 97 participants · Start Jun 10, 2019 · Primary completion Oct 31, 2023
Drug: Talabostat; Pembrolizumab · For: Prostate Cancer; Neuroendocrine Tumors; Small Cell Carcinoma
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 12 sites in all
Hope Biosciences LLCIndustry
NCT04063215 · 24 participants · Start Jan 1, 2020 · Primary completion Oct 25, 2024
Drug: HB-adMSCs · For: Traumatic Brain Injury
Sites: Houston, Texas
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)Completed
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06637423 · 35 participants · Start Dec 20, 2024 · Primary completion Sep 30, 2026
Drug: Sacituzumab tirumotecan; Rescue medication and 1 more · For: Non-Muscle Invasive Bladder Cancer
Sites: Bakersfield, California; Tampa, Florida; Chicago, Illinois · 13 sites in all
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)Pivotal-lookingCompleted
ALX Oncology Inc.Industry
NCT05002127 · 127 participants · Start Jan 15, 2022 · Primary completion May 24, 2024
Drug: Evorpacept (ALX148); Trastuzumab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma
Sites: Anaheim, California; Los Angeles, California; Nashville, Tennessee · 83 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03929666 · 74 participants · Start Aug 22, 2019 · Primary completion Aug 30, 2025
Drug: ZW25 (Zanidatamab); Capecitabine and 6 more · For: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Sites: Los Angeles, California; Newport Beach, California; Tampa, Florida · 23 sites in all
Evaxion Biotech A/SIndustry
NCT05309421 · 17 participants · Start Sep 19, 2022 · Primary completion Apr 7, 2026
Drug: EVX-01; Pembrolizumab 25 MG/ML · For: Melanoma Stage IV; Unresectable Melanoma
Sites: Wollstonecraft, Australia; Nedlands, Australia; Milan, Italy · 4 sites in all
Cothera Bioscience, IncIndustry
NCT05263583 · 14 participants · Start Dec 3, 2022 · Primary completion Feb 12, 2025
Drug: Sepantronium Bromide · For: High-grade B-cell Lymphoma; Burkitt Lymphoma; Lymphoma, B-Cell and 6 more
Sites: Beijing, China; Guangzhou, China; Henan, China · 11 sites in all
Enzychem Lifesciences CorporationIndustry
NCT03104595 · 28 participants · Start Oct 30, 2017 · Primary completion Nov 26, 2019
Drug: EC-18 · For: Febrile Neutropenia
Sites: Gyeonggi-do, South Korea; Seoul, South Korea · 3 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04704219 · 160 participants · Start Feb 23, 2021 · Primary completion Jan 27, 2025
Drug: Pembrolizumab; Lenvatinib · For: Renal Cell Carcinoma
Sites: Washington D.C., District of Columbia; Billings, Montana; Las Vegas, Nevada · 56 sites in all
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05805501 · 199 participants · Start Apr 21, 2023 · Primary completion Oct 5, 2026
Drug: Tobemstomig; Tiragolumab and 2 more · For: Renal Cell Carcinoma
Sites: Birmingham, Alabama; Orange, California; Atlanta, Georgia · 42 sites in all
- A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the BladderPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT04919512 · 163 participants · Start Jul 7, 2022 · Primary completion Feb 4, 2025
Drug: TAR-200; Cetrelimab · For: Urinary Bladder Neoplasms
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 109 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05852691 · 83 participants · Start Jul 18, 2023 · Primary completion Oct 15, 2026
Drug: Tobemstomig; Pembrolizumab and 1 more · For: Breast Cancer
Sites: Los Alamitos, California; New York, New York; Charlotte, North Carolina · 36 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03533283 · 211 participants · Start May 8, 2018 · Primary completion Oct 22, 2026
Drug: Glofitamab; Atezolizumab and 4 more · For: Non-Hodgkins Lymphoma
Sites: Charlotte, North Carolina; Ghent, Belgium; Aarhus N, Denmark · 20 sites in all
- A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung CancerPivotal-lookingCompleted
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05635708 · 418 participants · Start Feb 10, 2023 · Primary completion Dec 19, 2025
Drug: Tislelizumab; BGB-A445 and 7 more · For: Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer
Sites: Los Angeles, California; Boston, Massachusetts; New York, New York · 61 sites in all
- Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerPivotal-lookingCompleted
Theriva Biologics SLIndustry
NCT05673811 · 112 participants · Start Jan 10, 2023 · Primary completion Mar 28, 2025
Drug: Nab-paclitaxel; Gemcitabine · For: Pancreatic Adenocarcinoma; Metastatic
Sites: Newport Beach, California; Sacramento, California; Louisville, Kentucky · 17 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.